Zobrazeno 1 - 10
of 80
pro vyhledávání: '"Alison Conlin"'
Autor:
Alissa M. Michel, Haeseung Yi, Jacquelyn Amenta, Nicole Collins, Anna Vaynrub, Subiksha Umakanth, Garnet Anderson, Katie Arnold, Cynthia Law, Sandhya Pruthi, Ana Sandoval-Leon, Rachel Shirley, Maria Grosse Perdekamp, Sarah Colonna, Stacy Krisher, Tari King, Lisa D. Yee, Tarah J. Ballinger, Christa Braun-Inglis, Debra A. Mangino, Kari Wisinski, Claudia A. DeYoung, Masey Ross, Justin Floyd, Andrea Kaster, Lindi VanderWalde, Thomas J. Saphner, Corrine Zarwan, Shelly Lo, Cathy Graham, Alison Conlin, Kathleen Yost, Doreen Agnese, Cheryl Jernigan, Dawn L. Hershman, Marian L. Neuhouser, Banu Arun, Katherine D. Crew, Rita Kukafka
Publikováno v:
BMC Medical Informatics and Decision Making, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Women with high-risk breast lesions, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have a 4- to tenfold increased risk of breast cancer compared to women with non-proliferative breast disease. Despite high
Externí odkaz:
https://doaj.org/article/7ac042041f3a4b14993e75986bbff3f6
Autor:
David B. Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William L. Redmond, Maritza Martel, Zhaoyu Sun, Mary B. Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert S. Seitz, Tyler J. Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter J. Urba, Heather L. McArthur
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and bioma
Externí odkaz:
https://doaj.org/article/0206d7fb11584f5ab468ac8a9e5bed64
Autor:
Nikesha Gilmore, Supriya Mohile, Lianlian Lei, Eva Culakova, Mostafa Mohamed, Allison Magnuson, Kah Poh Loh, Ronald Maggiore, Elizabeth Belcher, Alison Conlin, Lora Weiselberg, Mary Ontko, Michelle Janelsins
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-11 (2021)
Abstract Background Frailty is associated with an increased risk of chemotherapy toxicity. Cellular markers of inflammation can help identify patients with frailty characteristics. However, the role of cellular markers of inflammation in identifying
Externí odkaz:
https://doaj.org/article/7390ec29a6d94d96a8c26a9f66ea8d32
Autor:
Sara M. Tolaney, Muralidhar Beeram, J. Thaddeus Beck, Alison Conlin, E. Claire Dees, Shannon L. Puhalla, Brent N. Rexer, Howard A. Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N. Moore, Allison M. Manuel, Andrew Lithio, Gregory L. Price, Sonya C. Chapman, Lacey M. Litchfield, Matthew P. Goetz
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
BackgroundCyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherap
Externí odkaz:
https://doaj.org/article/0ebf489cd41e4cb59d2713c43b686f6f
Autor:
Heather McArthur, William Redmond, Walter Urba, Yoshinobu Koguchi, Valerie Conrad, David Page, Nathan Polaske, Alison Conlin, Venkatesh Rajamanickam, Brady Bernard, Isaac Kim, Brie Chun, Joanna Pucilowska, Shu Ching Chang, Benjamin Nikitin, Paul Fields, Mark Schmidt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/cce097551a684be5ba030ca746e785a7
Autor:
Katherine D. Crew, Garnet Anderson, Kathryn Arnold, Andrew Stieb, Jacquelyn N. Amenta, Cynthia Law, Ana Sandoval-Leon, Sarah Colonna, Tari King, Debra Mangino, Sandhya Pruthi, Maria Grosse Perdekamp, Christa Braun-Inglis, Stacy Krisher, Lisa Yee, Danielle Bertoni, Samantha Seaward, Kari B. Wisinski, Justin Floyd, Corrine Zarwan, Tarah J. Ballinger, Lindi VanderWalde, Masey M. Ross, Preston Steen, Shelly Lo, Alison Conlin, Kathleen Yost, John Ellerton, Erin Lin, Holly J. Pederson, Sagar Sardesai, Cheryl Jernigan, Dawn Hershman, Marian L. Neuhouser, Banu K. Arun, Rita Kukafka
Publikováno v:
Cancer Research. 83:OT1-15
Background: Despite evidence of substantial breast cancer risk reduction, few high-risk women adopt chemopreventive medications such as selective estrogen receptor modulators (SERMs) or aromatase inhibitors (AIs). Women with benign breast disease, su
Autor:
Katherine Sanchez, Alison Conlin, Parvin Peddi, Sasha Stanton, Janet Ruzich, Kelly Perlewitz, Yaping Wu, Nicole Moxon, Staci Mellinger, Zhaoyu Sun, William Redmond, David B Page
Publikováno v:
Cancer Research. 82:OT1-18
Background: In stage II/III TNBC, pembrolizumab when combined with chemotherapy (doxorubicin, cyclophosphamide, paclitaxel [ACT], and carboplatin) improves event free survival and pathologic complete response (pCR) rate (Keynote-522 study).1 Novel co
Autor:
Julie R. Gralow, Anne F. Schott, Lisa Welter, Lajos Pusztai, George Somlo, Ernie Balcueva, Gabriel N. Hortobagyi, Philip A. Dy, Daniel F. Hayes, Halle C. F. Moore, Peter Kuhn, Danika L. Lew, Alison Conlin, James W. Hicks, William E. Barlow, Christina Yeon, Debasish Tripathy
Publikováno v:
Clinical Cancer Research. 28:611-617
Purpose: Metastatic hormone receptor (HR)-positive, HER2-negative breast cancer is an important cause of cancer mortality. Endocrine treatment with or without additional targeted therapies has been the mainstay of treatment. This trial was designed t
Autor:
Alison Conlin, Thomas Boulet, Georg Kunz, J.C. Alcedo, Andrea Fontana, Irene Wapnir, Norman Wolmark, Xavier Pivot, Max S. Mano, Adam Brufsky, S. Loibl, D. Tesarowski, Chunyan Song, Bella Kaufman, Youngsen Yang, Melanie Smitt, Mahasti Saghatchian, Martina Zimovjanova, Michael Untch, G. von Minckwitz, Jonathan Polikoff, Charles E. Geyer, S. Kuemmel, H. Liu, Eleftherios P. Mamounas, John Hackmann, Lisa H. Lam, C.-S. Huang, T. Kuehn, Michael P. DiGiovanna
Publikováno v:
Annals of Oncology. 32:1005-1014
Background In the KATHERINE study (NCT01772472), patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recu
Autor:
David Page, Joanna Pucilowska, Brie Chun, Isaac Kim, Katherine Sanchez, Nicole Moxon, Staci Mellinger, Yaping Wu, Yoshinobu Koguchi, Valerie Conrad, William Redmond, Zhaoyu Sun, Maritza Martel, Mary Campbell, Alison Conlin, Anupama Acheson, Reva Basho, Philomena McAndrew, Mary El-Masry, Dorothy Park, Laura Bennetts, Robert Seitz, Tyler Nielsen, Kimberly McGregor, Venkatesh Rajamanickam, Brady Bernard, Walter Urba, Heather McArthur
Background Chemoimmunotherapy with anti-programmed cell death 1/ligand 1 and cytotoxic chemotherapy is a promising therapeutic modality for women with triple-negative breast cancer, but questions remain regarding optimal chemotherapy backbone and bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46c9e6dabbe18a89eeabefa52b420552
https://doi.org/10.21203/rs.3.rs-1954085/v1
https://doi.org/10.21203/rs.3.rs-1954085/v1